Antiviral Combination Therapies Market

The triple combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b holds promising potentials in the treatment of coronavirus (COVID-19). Researchers in healthcare companies and organizations are referring historical findings of the lopinavir-ritonavir & ribavirin combination, which was effective in lowering the morbidity and mortality rate of the then SARS (Severe Acute Respiratory Syndrome). Since COVID-19 is a novel viral infection, companies in the antiviral combination therapies market are increasing their research in triple combination therapies to advance in the coronavirus treatment.Many Coronavirus patients are in need for intensive respiratory support in hospitals. Since lopinavir?ritonavir and interferon beta-1b were found to reduce the viral load in SARS, companies in the antiviral combination therapies market are increasing focus in these drugs to innovate in antiviral drugs for coronavirus. It has been found that multiple antiviral drugs help to improve patient outcomes as compared to the consumption of single drug treatments.

Antiviral Combination Therapies Market contains market size and forecasts of Antiviral Combination Therapies in Global, including the following market information:

Global Antiviral Combination Therapies Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Antiviral Combination Therapies market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

NRTI/NNRTI Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Antiviral Combination Therapies include Celltrion, Inc., GlaxoSmithKline plc, Gilead Sciences, Inc., AbbVie, Inc., Bristol-Myers Squibb Company, Janssen Global Services, F. Hoffmann-La Roche Ltd., Cipla, Inc. and Mylan N.V. and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Antiviral Combination Therapies companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Antiviral Combination Therapies Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Antiviral Combination Therapies Market Segment Percentages, by Type, 2021 (%)

NRTI/NNRTI

Integrase Inhibitor/NRTI

NRTI/Protease Inhibitor

Others

Global Antiviral Combination Therapies Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Antiviral Combination Therapies Market Segment Percentages, by Application, 2021 (%)

HIV

Hepatitis

Others

Global Antiviral Combination Therapies Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Antiviral Combination Therapies Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Antiviral Combination Therapies revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Antiviral Combination Therapies revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Celltrion, Inc.

GlaxoSmithKline plc

Gilead Sciences, Inc.

AbbVie, Inc.

Bristol-Myers Squibb Company

Janssen Global Services

F. Hoffmann-La Roche Ltd.

Cipla, Inc.

Mylan N.V.

Merck & Co., Inc.